Please login to the form below

Not currently logged in
Email:
Password:

Rigel Pharmaceuticals

This page shows the latest Rigel Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Rigel and Ultragenyx claim approvals for rare drugs

Rigel and Ultragenyx claim approvals for rare drugs

The FDA gave the go-ahead to a pair of rare disease therapies this week, both marking the first-ever approvals for developers Rigel Pharmaceuticals and Ultragenyx. ... Rigel is also developing it for additional indications, including autoimmune

Latest news

  • Rigel shaken after fostamatinib misses phase III trial target Rigel shaken after fostamatinib misses phase III trial target

    Shares in Rigel Pharmaceuticals fell yesterday after it revealed its lead drug candidate fostamatinib had failed a phase III trial in chronic/persistent immune thrombocytopenia (ITP), a disease leading to reduced ... In August, Rigel reported the same 18

  • Rigel plans job cuts in R&D restructure Rigel plans job cuts in R&D restructure

    Rigel plans job cuts in R&D restructure. Follows failure of fostamatinib disodium in rheumatoid arthritis trial. ... Rigel Pharmaceuticals plans to cut 30 jobs as part of a restructure of its research efforts following the failure of fostamatinib

  • AstraZeneca boosts R&D prospects with Pearl acquisition AstraZeneca boosts R&D prospects with Pearl acquisition

    Pharma and Omthera Pharmaceuticals. ... Other respiratory prospects for AZ include the JAK inhibitor R256 licensed last year from Rigel Pharmaceuticals in a deal that could be worth up to $100m.

  • AstraZeneca strikes $100m deal for chronic asthma candidate AstraZeneca strikes $100m deal for chronic asthma candidate

    AstraZeneca strikes $100m deal for chronic asthma candidate. Licenses Rigel Pharmaceuticals' inhaled JAK inhibitor R256. ... AstraZeneca (AZ) has licensed a pre-clinical candidate for chronic asthma from clinical-stage drug development company Rigel

  • Pfizer returns asthma drug to Rigel

    Pfizer returns asthma drug to Rigel. Pfizer is returning full rights to a clinical-stage inhaled asthma drug to Rigel Pharmaceuticals. ... Pfizer is returning full rights to a clinical-stage inhaled asthma drug to Rigel Pharmaceuticals as part of a

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Salix Pharmaceuticals/ Valeant Pharmaceuticals. GI products. Corporate acquisition. 14, 500. Flexus Biosciences/ BMS. ... Collaboration - develop and commercialise. 342. Rigel Pharmaceuticals/ BMS. Small molecule TGF beta receptor kinase inhibitors -

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics